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Brain-derived neurotrophic factor (BDNF) and its receptor tyrosine kinase TrkB support
neuronal survival during development and promote connectivity and plasticity in the adult
brain. Decreased BDNF signaling is associated with the pathophysiology of depression and
the mechanisms underlying the actions of antidepressant drugs (AD). Several transgenic
mouse models with decreases or increases in the amount of BDNF or the activity of TrkB
signaling have been created. This review summarizes the studies where various mouse
models with increased or decreased BDNF levels or TrkB signaling were used to evaluate
the role of BDNF signaling in depression-like behavior. Although a large number of models
have been employed and several studies have been published, no clear-cut connections
between BDNF levels or signaling and depression-like behavior in mice have emerged.
However, it is clear that BDNF plays a critical role in the mechanisms underlying the
actions of AD.
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The neurotrophin brain-derived neurotrophic factor (BDNF)
supports neuronal survival during development and promotes
connectivity and plasticity in the adult brain by activating its
tyrosine kinase receptor TrkB (Park and Poo, 2013). Impaired
BDNF signaling through TrkB is associated with the pathophys-
iology of mood disorders and neuronal plasticity promoted by
BDNF underlies some of the actions of antidepressant drugs
(AD) (Duman and Monteggia, 2006; Castrén et al., 2007). BDNF
mRNA and protein levels in the rodent hippocampus (HC) cor-
relate with depressive behaviors and with anatomical changes
in the HC induced by stress (Duman et al., 1997; Duman and
Monteggia, 2006). Similar findings have also been reported in the
brains of depressed patients (Sheline et al., 1996; Bremner et al.,
2000).
Direct injection of BDNF into the dentate gyrus (DG) or CA3
regions of the HC, which are brain regions implicated in spa-
tial memory and in the regulation of emotionality and mood,
leads to antidepressant-like effects and to enhancement of the
antidepressant-like activity of paroxetine in rodent behavioral
despair models (Shirayama et al., 2002; Deltheil et al., 2008).
Tyrosine kinase inhibitor K252a blocks this effect, suggesting
that the antidepressant-like behavior of BDNF is dependent on
TrkB activity (Shirayama et al., 2002). Similar antidepressant-like
behavioral effects were observed when BDNF was injected into
the midbrain region, which contains serotonergic neurons pro-
jecting to forebrain regions (Siuciak et al., 1997). Furthermore,
peripheral administration of BDNF produces an antidepressant-
like effect similar to the effects observed with intracranial
administration (Schmidt and Duman, 2010). By contrast, direct
injection of BDNF into the ventral tegmental area, a brain area
that contains dopaminergic cell bodies, causes depression-like
behavior, and blockade of BDNF signaling in the nucleus accum-
bens, a brain area involved in reward and hedonic behavior,
produces antidepressant-like behavior (Eisch et al., 2003; Berton
et al., 2006). Therefore, the effects of BDNF on depression-like
behavior depend upon the functional role of the circuitry that is
targeted.
Chronic treatment with ADs, electroconvulsive shock treat-
ment, and physical exercise all increase BNDF mRNA and pro-
tein levels in both animals and humans (Nibuya et al., 1995;
Zetterström et al., 1998; Russo-Neustadt et al., 1999; Chen et al.,
2001; Coppell et al., 2003; Duman et al., 2008; Marais et al.,
2009). Importantly, chronic treatment with ADs restores stress-
induced changes in BDNF mRNA levels in experimental animals
(Nibuya et al., 1995; Duman and Monteggia, 2006). However,
there is evidence that the regulation of BDNF expression by
ADs is more complex. Some studies report that BDNF mRNA
levels decrease shortly after AD administration (Coppell et al.,
2003; Kozisek et al., 2008). Furthermore, different classes of
ADs activate TrkB signaling after both acute and long-term
administration (Saarelainen et al., 2003; Rantamäki et al., 2007),
and this TrkB mediated BDNF signaling is essential for the
antidepressant-like effects of ADs in rodents (Saarelainen et al.,
2003; Ibarguen-Vargas et al., 2008).
BDNF AND HUMANMOOD DISORDERS
A comprehensive review of the role of BDNF in mood disorders
is beyond the scope of this review, but some remarks are useful to
provide a perspective for the rodent data reviewed below. BDNF
and TrkB receptor levels in the brains and BDNF concentrations
in the plasma of suicidal subjects are decreased (Dwivedi et al.,
2003; Kim et al., 2007). Furthermore, AD treatment increases
BDNF levels in the HC of postmortem human brains (Chen et al.,
2001).
A single nucleotide polymorphism (SNP) in the human BDNF
gene in which valine (Val) is substituted with methionine (Met)
in codon 66 (Val66Met) reduces activity-dependent BDNF release
and impairs hippocampal function (Egan et al., 2003). This SNP
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is only observed in humans and is expressed throughout the gen-
eral population (Val/Met: 20–50%, Met/Met 3–20%), but is more
common in Asian than in Caucasian populations (Verhagen et al.,
2008). HeterozygousMet allele carriers have smaller hippocampal
volumes and perform worse in hippocampal-dependent memory
tasks than people with the Val/Met allele (Egan et al., 2003). No
clear connections exist between this SNP and clinical depression
or anxiety (Gratacos et al., 2007; Verhagen et al., 2008; Gyekis
et al., 2013). However, there is evidence for a higher sensitivity
to stressful life events among Met-allele carriers (Kaufman et al.,
2006; Hosang et al., 2014). Unexpectedly, heterozygous met-allele
carriers show a better response to antidepressant drug treatments
than homozygous (Val/Val or Met/Met) carriers (Niitsu et al.,
2013). By contrast, a mouse model of the Val66Met polymor-
phism suggests an impaired response to antidepressants in Met
carrying mice (Chen et al., 2006). Potential associations between
the Val66Met SNP and other mental disorders, such as substance
abuse, eating disorders and schizophrenia have, however, been
reported (Gratacos et al., 2007; Eisenberg et al., 2013).
BDNF is abundantly expressed in blood platelets, therefore,
BDNF levels in human serum are relatively high (Karege et al.,
2005). Several clinical studies demonstrate that BDNF serum lev-
els are decreased in depressed patients and that these levels recover
following successful antidepressant treatment (Karege et al., 2005;
Monteleone et al., 2008; Sen et al., 2008). Unfortunately, mouse
blood platelets appear to contain little or no BDNF and, con-
sequently, BDNF levels in mouse serum are low. This species
difference has greatly hampered mechanistic studies into this
interesting and consistent finding of the relationship between
mood disorders and serum BDNF levels.
GENETIC MOUSE MODELS OF ALTERED BDNF AND TrKB
A substantial number of genetically modified mouse models with
altered BDNF expression or TrkB signaling have been produced.
There are several distinct approaches that have been taken to
genetically modify BDNF signaling. First, the most common
method involves knock down of BDNF expression from either
the whole organism or from a spatially restricted region. Second,
TrkB signaling is inhibited through either TrkB knockout (KO)
or other strategies that decrease TrkB activity. Third, there are
gain-of-function models that enhance either BDNF expression
or TrkB activity. This review will summarize the results from
these BDNF and TrkB genetic models that are related to mood
disorders.
DECREASED BDNF LEVELS
Ernfors et al. (1994) produced mutant mice lacking BDNF,
the constitutive BDNF KO, in the early 1990s. Homozygous
BDNF KO mice have severe health problems and die soon after
birth (Ernfors et al., 1994). However, heterozygous BDNF KO
[BDNF(±)] mice are vital and fertile. Their BDNF mRNA and
protein levels in brain are approximately 50% of their wild-
type littermates (Korte et al., 1995; MacQueen et al., 2001;
Ibarguen-Vargas et al., 2009). This deficiency strongly down
regulates the early postnatal signaling capacity of TrkB recep-
tors. However, in adult mice, TrkB phosphorylation appears
to be only slightly altered, if at all (Rantamäki et al., 2011).
Similarly, forebrain-specific conditional BDNF KO mice have
normal TrkB phosphorylation levels (Rantamäki et al., 2011).
During normal postnatal development, the responsiveness of
TrkB to BDNF is decreased, and TrkB simultaneously gains
the ability to be activated by BDNF-independent transactivating
mechanisms (Knüsel et al., 1997; Di Lieto et al., 2012). The reason
and significance of these findings are currently unknown but it
is possible that BDNF-independent TrkB activation mechanisms,
such as zinc or adenosine induced transactivation (Lee and Chao,
2001; Huang et al., 2008), predominate in the adult brain.
The behavioral phenotypes of BDNF knock down mice are
widely studied; however, results vary from one laboratory to
another (Table 1). BDNF(±) mice have increased appetite and are
usually obese (Lyons et al., 1999; Kernie et al., 2000; Chen et al.,
2006). These mice appear to have normal visual, auditory, and
nociceptive senses (Liu et al., 2004; Bath et al., 2008); however,
they have olfactory system impairments (Liu et al., 2004; Bath
et al., 2008). When tested in a novel environment, the locomotor
activity of these mice does not differ from their wildtype litter-
mates (Lyons et al., 1999; MacQueen et al., 2001; Chourbaji et al.,
2004; Chen et al., 2006; Ibarguen-Vargas et al., 2009; Marais et al.,
2009; Lindholm et al., 2012; Psotta et al., 2013; however see Kernie
et al., 2000). BDNF(±) mice also showmild impairments in learn-
ing and memory. They display impaired contextual memory but
have normal cued memory (Linnarsson et al., 1997; Liu et al.,
2004; Chen et al., 2006). BDNF(±) mice also display impaired fear
extinction behavior in a fear conditioning paradigm (Psotta et al.,
2013). However, these findings are not consistent throughout all
studies (Chourbaji et al., 2004; Uutela et al., 2012). Importantly,
there are humans with heterozygous deletions of BDNF or TrkB,
and these people are obese and suffer from mental retardation
(Yeo et al., 2004; Gray et al., 2006).
The anxiety- and depression-like behavioral phenotypes of
these mice are even more complex. Some of the studies found
that anxiety-like behaviors of BDNF(±) mice is indistinguishable
from littermate controls (Chourbaji et al., 2004; Ibarguen-Vargas
et al., 2009; Lindholm et al., 2012), whereas others found that
these mice are more aggressive and display increased anxiety
(Lyons et al., 1999; Chen et al., 2006; Li et al., 2010). These
mice do not show depression-like behavior in models of behav-
ior despair (such as the forced swim or tail suspension tests)
(MacQueen et al., 2001; Saarelainen et al., 2003; Chourbaji et al.,
2004; Duman et al., 2007; Ibarguen-Vargas et al., 2009), but
they do show depression-like behavior in the learned helpless-
ness test (MacQueen et al., 2001). Furthermore, when exposed to
stress, BDNF(±) mice demonstrate an anxiety- and depression-
like behavioral phenotype (Duman et al., 2007; Carola and Gross,
2010). Several studies have consistently shown that BDNF(±)
mice are resistant to classical ADs in models of behavioral despair
(Saarelainen et al., 2003; Ibarguen-Vargas et al., 2009; Lindholm
et al., 2012). Thus, BDNF(±) mice do not show any clear base-
line anxiety- or depression-like behaviors, but they are more
vulnerable to stress and the effects of ADs are blocked in these
mice.
Spatially restricted BDNF KOmouse lines have been produced
by crossing mice carrying floxed BDNF (flBDNF) alleles with
lines expressing Cre recombinase under a tissue-specific promoter
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Table 1 | Behavioral results of heterozygous BDNF-KO mice.
Behavioral tests Result Background Reference
BW, LA and FI Increased appetite and weight, and decreased
locomotor activity in BDNF(±) mice, but not in
heterozygous NT4/5, NT3, TrkC, or TrkA
knockout mice
C57Bl/6 and 129Sv mixed F2
background
Kernie et al., 2000
Anhedonia, EPM, FST, LH,
NOR, OF, PA, SP, staircase
No differences in most of tests. Longer escape
latencies in LH
C57Bl/6 and 129Sv mixed background MacQueen et al., 2001
NSF, OF, RI, TST No behavioral changes, effects of ADs blocked in
heterozygous mice
C57Bl/6 and 129Sv mixed background Ibarguen-Vargas et al., 2009
EZM, FC, FST, LD, novel
cage, OF, RR
No behavioral changes C57Bl/6 and 129Sv mixed background Chourbaji et al., 2004
EPM, OF Increased sensitivity to pre/postnatal maternal
environment (high or low maternal care)
C57Bl/6J and/or BALB/c Carola and Gross, 2010
BW, FI, OF, RI Increased appetite, weight and aggressiveness C57Bl/6 Lyons et al., 1999
BW, EPM, FC, LA, NSF, OF,
RI
Increased weight, aggressiveness, and
anxiety-like behavior, impaired contextual but
intact cue memory. No changes in locomotor
activity
C57Bl/6J Chen et al., 2006
FST No behavioral changes, effects of ADs blocked in
heterozygous mice
129Sv X BALB/c Saarelainen et al., 2003
FC, pain, vision and auditory
tests
No changes in senses or baseline freezing,
impairment in contextual memory-, but not in
cue memory test
C57Bl/6 Liu et al., 2004
FC, OF No changes in locomotor activity, but adult
animals have impaired fear extinction learning
C57Bl/6J Psotta et al., 2013
Spontaneus olfactory
discrimination
Impairment in olfactory system C57Bl/6 Bath et al., 2008
FST Depression-like behavior after stress or MEK
inhibitor
C57Bl/6? Duman et al., 2007
EPM, OF Increased anxiety-like behavior, no changes in
locomotor activity
C57Bl/6 Li et al., 2010
ASR, BW, FC, OF, RR, WM No behavioral changes, increased weight C57Bl/6 Uutela et al., 2012
WM Impaired learning and memory 129/J x BALB/c Linnarsson et al., 1997
FST, OF No behavioral changes, effects of ADs blocked in
heterozygous mice
C57Bl/6J Lindholm et al., 2012
Abbreviations: ASR, Acustic startle response; BW, Body weight; EPM, elevated plus-maze; FC, fear conditioning; FI, food intake; FST, forced swimming test; EZM,
elevated zero maze; LA, locomotor activity; LD, light-dark box; LH, learned helplessness; NOR, novel object recognition; NSF, novelty suppressed feeding; OF, open
field; PA, passive avoidance; RI, resident-intruder test; RR, RotaRod; SP, sucrose preference; TST, tail suspension test; WM, water maze.
(Table 2). Mood-related behaviors have been investigated using
Cre lines directed by the α-calcium/calmodulin-dependent pro-
tein kinase II (CamK) promoter, which drives expression in post-
mitotic neurons (Rios et al., 2001). These mice showed increased
food intake, weight gain, anxiety-like behavior, and hyperactivity
(Rios et al., 2001). Monteggia et al. (2007) also investigated two
conditional BNDF KO mice lines. One line crossed flBDNF mice
with human glial fibrillary acidic protein (GFAP)-Cre mice and
the other with CaMKII-Cre. In GFAP-Cre mice, Cre recombinase
is broadly expressed in forebrain regions during late embryoge-
nesis, and in CamK-Cre mice it is expressed in similar regions
during postnatal development (Monteggia et al., 2007). BDNF
mRNA levels in the CamK-Cre x flBDNF mice were signifi-
cantly reduced in the HC and the dorsal cerebral cortex, while
GFAP-Cre x flBDNF mice lacked BDNF mRNA in a nearly iden-
tical pattern. Male conditional KOs from both lines showed
hyperactivity but normal depression-like behavior. Female mice
displayed normal activity scores but had increased depression-like
behavior. Furthermore, ADs failed to have any effect in either sex.
Chan et al. (2006) also produced two conditional BDNF KOmice
lines, crossing flBDNF mice with either Nestin or CamK-Cre,
which resulted in pre- and postnatal recombination, respectively.
The authors found that both BDNF KO mouse lines displayed
hyperactivity and aggressive behavior. In addition, both BDNF
KOmouse lines displayed depression-like behavior in the tail sus-
pension test, but lower immobility scores in the forced swim test
when compared to wildtype littermates.
Inducible mice with temporally restricted manipulations of
BDNF have also been made. In these mice, a pharmacologi-
cal compound, such as tamoxifen or doxycycline, is used to
either activate or inactivate gene expression. Monteggia et al.
(2004) used this method to produce triple transgenic (NSE-tTA×
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Table 2 | Behavioral results of transgenic BDNF mice.
Mutant mice Behavioral tests Result Background Reference
Inducible BDNF-KO
in forebrain: adult KO
BW, FC, LA, RI, pain
test
No changes in BW, LA, aggressiviness, cue
memory or pain sensitivity, impaired
contextual memory
Mixed background:
BL6/SJL × ICR × ICR ×
Bl6/sv129
Monteggia et al., 2004
Inducible BDNF-KO
in forebrain: early KO
BW, FC, FST, LA, RI No changes in BW or aggressiviness,
hyperactive phenotype, impaired contextual
and cue memory
Mixed background:
BL6/SJL × ICR × ICR ×
Bl6/sv129
Monteggia et al., 2004
Inducible BDNF-KO
in forebrain
BW, FST, LA, NSF,
OF, SP, TST
BDNF-KO increases vulnerability to chronic
stress induced anxiogenic and anhedonic
behaviors in female, but not in male mice
Mixed background:
BL6/SJL × ICR × ICR ×
Bl6/sv129
Autry et al., 2009
Inducible BDNF-KO
in forebrain
FST Antidepressant-like effect of ketamine was
blocked
Mixed background:
BL6/SJL × ICR × ICR ×
Bl6/sv129
Autry et al., 2011
Conditional
BDNF-KO: postnatal
brain
BW, FI, LA, LD Increased appetite, weight and anxiety-like
behavior, hyperactivity
Mixed background Rios et al., 2001
Conditional BDNF-KO LA, EPM, FST, OF, SP Hyperactivity in male mice, depression-like
behavior in female mice. Effects of ADs
blocked in both sex in FST
– Monteggia et al., 2007
BDNF (Val66Met)
polymorphism
EPM, FC, LA, NSF,
OF, RI
Increased weight, aggressiveness, and
anxiety-like behavior, impaired contextual but
intact cue memory. No changes in locomotor
activity
C57Bl/6J Chen et al., 2006
BDNF (Val66Met)
polymorphism
Spontaneus olfactory
discrimination
Impairment in olfactory system C57Bl/6 Bath et al., 2008
BDNF (Val66Met)
polymorphism
EPM, FST, NSF, OF,
SP, TM, WM
Depression- and anxiety-like behavior, poor
spontaneus alteration only after stress.
Rescuing effect of desipramine but not
fluoxetine in FST
– Yu et al., 2012
BDNF (Val66Met)
polymorphism
EPM, OF Increased anxiety-like behavior, no changes in
locomotor activity. Music rescues anxiogenic
behavior
C57Bl/6 Li et al., 2010
BDNF
overexpressing
WM Heterozygous but not homozygous mice
showed improved learning and memory
C57Bl/6J Nakajo et al., 2008
BDNF
overexpressing in
exitatory neurons in
forebrain
EPM, FST, OF Anxiogenic- and antidepressant-like behavior.
No changes in locomotor activity
C57Bl/6 Govindarajan et al., 2006
BDNF
overexpressing,
hemizygous
ASR, EPM, FC, FST,
LD, OF, PPI, RR, SA,
TM, TST
Impaired working memory, but normal
contextual and cue memory, impairments in
ASR and PPI, anxiety-like behavior in LD but
not in EPM. Normal motor and locomotor
function, no changes in depression-like
behavior
C57Bl/6J Papaleo et al., 2011
Abbreviations: ASR, Acustic startle response; BW, body weight; EPM, elevated plus-maze; FC, fear conditioning; FI, food intake; FST, forced swimming test; LA,
locomotor activity; LD, light-dark box; NSF, novelty suppressed feeding; OF, open field; PPI, pre-pulse inhibition; RI, resident-intruder test; RR, rotarod; SA, social
approach; SP, sucrose preference; TST, tail suspension test; TM, T-maze; WM, water maze.
TetOp-Cre × floxed BDNF) mice in which BDNF expression can
be knocked out upon withdrawal of doxycycline from the diet.
When doxycycline was absent during early development, these
mice showed a hyperactive phenotype and impairments in con-
textual and cued memory tasks. By contrast, when doxycycline
was absent during adulthood these mice had a milder phenotype
only showing some impairments in contextual memory tasks.
In addition, mice with adulthood BDNF knock down do not
show any baseline depression-like behaviors in behavioral despair
models, however, antidepressant-like effects are lost (Monteggia
et al., 2004; Autry et al., 2011). Autry et al. (2009) also exam-
ined the effects of chronic unpredictable stress (CUS) on similar
mice. The authors found that female mice with induced BDNF
knock down were more vulnerable to CUS-induced anxiogenic
and anhedonic behaviors while male knock down mice did not
differ from wildtype littermates.
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To study more localized effects of BDNF deletion, Adachi
et al. (2008) injected adeno-associated virus (AAV)-driven Cre
into either the DG or CA1 area of flBDNF mice to specifi-
cally delete BDNF expression in these areas. The authors found
that loss of BDNF in the DG or CA1 did not affect locomotor
activity, contextual memory, cued memory, or baseline anxiety-
like, depression-like and hedonic behaviors. However, deletion
of BDNF in the DG, but not CA1, blocked the effect of ADs in
a behavioral despair model. By contrast, local lentiviral knock
down of BDNF in the rat dorsal DG results in anhedonic and
depression-like behaviors (Taliaz et al., 2010). Signs of anhedonia
were also seen when BDNF knock down was specifically targeted
to the ventral subiculum, a region that has close connections with
brain centers that regulate emotional behavior. However, when
BDNF knock down was directed to the dorsal CA3 region of the
HC, no effects were observed (Taliaz et al., 2010).
Chen et al. (2006) produced Val66Met SNP knock-in mice.
Similar to human Met carriers, both hetero- (Val/Met) and
homozygous (Met/Met) Met-mice showed decreased total hip-
pocampal volume and impaired contextual memory (Chen
et al., 2006). However, the cued memory and novel environ-
ment activity were similar in Met-mice and wildtype littermates.
Furthermore, Met/Met mice showed increases in weight, aggres-
siveness, and anxiety-like behaviors. In addition, the effects of
ADs in anxiety-related tasks were lost in these mice.
The Met-mice mice have also been tested in several other
studies. Both Val/Met and Met/Met knock-in mice show impair-
ments in a spontaneous olfactory discrimination test (Bath et al.,
2008), while Met/Met mice show anxiety-like behavior that can
be rescued by exposure to music (Li et al., 2010). In addition,
Val/Met mice show vulnerability to stress induced anxiety- and
depression-like behaviors, which can be rescued by some, but not
all, ADs (Yu et al., 2012). Both human and murine Met allele
carriers show impaired extinction of conditioned fear responses
(Soliman et al., 2010). However, similar to other transgenic
mouse models of BDNF, these mice have not conclusively clari-
fied the connection between BDNF and the pathophysiology of
depression.
Taken together, the large number of studies using mice with
decreased BDNF expression has not yielded any clear connec-
tions between depression and BDNF. Several of the studies found
opposing behavioral effects or no effects at all. Even though
BDNF(±) mice display a 50% reduction in BDNF levels through-
out their entire lifespan, their behavioral phenotype is mild and
varies from laboratory to laboratory. These discrepancies might
be due to developmental compensatory mechanisms, variations
in genetic backgrounds (Jacobson and Cryan, 2007), sex differ-
ences (Dalla et al., 2010), or inter-laboratory practices (Wahlsten
et al., 2003). Furthermore, conditional KOs and mice with the
Val/Met mutation have similar problems as BDNF(±) mice. The
behavioral results vary widely depending on the laboratory and
the spatial location and temporal timing of the transgenes.
INHIBITION OF TrKB SIGNALING
BDNF(±) mice and other approaches to decrease BDNF signaling
have not provided any conclusive evidence regarding the con-
nection between BDNF and depression-like behavior. Therefore,
there is growing interest in genetic models of TrkB signaling
(Table 3). Germline TrkB KO mice have serious developmental
problems and die soon after birth (Klein et al., 1993; Rohrer et al.,
1999). Only a few studies with heterozygous mice have been per-
formed. Allen et al. (2005) found disrupted circadian rhythm in
TrkB het mice. However, several conditional TrkB KOmouse lines
have been produced and have permitted analyses of the behav-
ioral effects of TrkB receptor deficiency that is spatially restricted
to various brain regions.
Crossing floxed TrkB KO mice with CamK-Cre mice produces
mice with TrkB deficiency in the HC and forebrain neocor-
tex starting at P15. These mice are viable and have normal
brain morphology (Minichiello et al., 1999). They show a hyper-
active phenotype with impulsivity but do not show baseline
depression-like behaviors inmodels of behavioral despair (Zörner
et al., 2003). They also do not display anxiety-like behavior.
However, the antidepressant effects of ketamine were blunted in
these mice (CamK-Cre; KO on P21) (Autry et al., 2011). Mice
with specific TrkB deletion in adult DG neuronal progenitors
(using nestin-CreERT2 mice) show decreased locomotor activ-
ity and increased anxiety-like behavior (Bergami et al., 2008). In
addition, these mice do not respond to chronic AD treatment
(Li et al., 2008).
As an alternative to decreasing TrkB signaling in mice
through conditional deletion of TrkB receptors, Saarelainen
et al. (2000) produced transgenic mice overexpressing the
truncated, dominant negative form of the TrkB receptor
(TrkB.T1; used as a heterozygous). When the TrkB.T1 recep-
tor is under the control of the Thy1 promoter, it is over-
expressed in postnatal neurons starting during the first few
postnatal weeks (Saarelainen et al., 2000). When maintained
on a CD2 (BALB/c × DBA/2) background, these mice dis-
play impaired long-term spatial memory (Saarelainen et al.,
2000) and do not respond to the ADs imipramine and
fluoxetine in behavioral despair models (Saarelainen et al.,
2003). When these mice are backcrossed to a C57BL/6J back-
ground for more than 10 generations, they showed normal
contextual learning and memory and normal social behav-
ior (Razzoli et al., 2011; Kemppainen et al., 2012). However,
these mice tend to avoid social situations when stressed
(Razzoli et al., 2011). Interestingly, recent findings indicate that
these mice show indifference toward the surrounding environ-
ment rather than depression-like behavior (unpublished data,
Lindholm et al.).
Chen et al. (2005) used another approach to inhibit TrkB sig-
naling and produced a knock-in mouse line with a single amino
acid mutation near the ATP binding site of the TrkB receptor
(TrkBF616A). This mutation does not influence the activity of
the receptor, but if the pharmacologically inert kinase inhibitor
1NMPP1 is given (Bishop et al., 1999), then the activity of the
TrkB receptor is inhibited. The advantage of these mice is that
TrkB activity can be specifically, rapidly, and reversibly blocked
without directly influencing the expression of the TrkB receptor.
TrkBF616Amice have been successfully used in Pavlovian condi-
tioningmodel and epilepsy studies (Johnson et al., 2008; Liu et al.,
2013), but large-scale behavioral studies using thesemice have not
yet been reported.
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Table 3 | Behavioral results of transgenic TrkB mice.
Mutant mice Behavioral tests Result Background Reference
Forebrain-specific TrkB-receptor
Knockout
EM, EZM, FST, NOR, OF Increased locomotor activity in OF
and mobility in FST. No changes in
anxiety-like behavior
C57Bl/6N × 129/sv
× CBA/J
Zörner et al., 2003
TrkB(±) Spontaneus olfactory
discrimination
Impairment in olfactory system C57Bl/6 Bath et al., 2008
TrkB(±) Circadian rythm Disrupted circadian rythm C57Bl/6 Allen et al., 2005
TrkB-KO in adult born neurons EPM, OF Decreased locomotor activity,
increased anxiety-like behavior
C57Bl/6 Bergami et al., 2008
TrkB-KO in adult born neurons NSF, TST No behavioral changes, effects of
ADs blocked
C57Bl/6 Li et al., 2008
Overexpressing catalytic TrkB
receptor (TrkB.TK+), used as
heterozygous
FST Antidepressant-like behavior CD2F1 (BALB/c ×
DBA/2)
Koponen et al., 2005
Overexpressing catalytic TrkB
receptor (TrkB.TK+), used as
heterozygous
CTA, EPM, FC, HP, LD,
OF, RR, WM, Y-maze
Anxiolytic-like behavior, enhanced
contextual and associative learning
and memory. No changes in
locomotor activity or coordination
CD2F1 (BALB/c ×
DBA/2)
Koponen et al., 2004
Overexpressing catalytic TrkB
receptor (TrkB.TK+), used as
heterozygous
OF, WM Normal contextual learning and
memory. Increased locomotor
activity in male, but not in female
mice
C57Bl/6 Kemppainen et al., 2012
Overexpressing truncated TrkB
receptor (TrkB.T1, dominant
negative), used as heterozygous
FST No behavioral changes, effects of
ADs blocked in heterozygous mice
CD2F1 (BALB/c ×
DBA/2)
Saarelainen et al., 2003
Overexpressing truncated TrkB
receptor (TrkB.T1, dominant
negative), used as heterozygous
WM Impairment in contextual learning
and memory
CD2F1 (BALB/c ×
DBA/2)
Saarelainen et al., 2000
Overexpressing truncated TrkB
receptor (TrkB.T1, dominant
negative), used as heterozygous
OF, WM Normal contextual learning and
memory
C57Bl/6 Kemppainen et al., 2012
Overexpressing truncated TrkB
receptor (TrkB.T1, dominant
negative), used as heterozygous
BW, SA Normal social behavior; stress
induces social avoidance. Normal
body weight
C57Bl/6 Razzoli et al., 2011
TrkBF616A, time controlled inhibition
of TrkB receptor
FC Inhibition of TrkB receptor prior to
testing prevents formation of fear
conditioning
C57Bl/6 Johnson et al., 2008
TrkBF616A, time controlled inhibition
of TrkB receptor
Inhibition of TrkB receptor prevents
status epilepticus
C57Bl/6 Liu et al., 2013
Abbreviations: BW, body weight; CTA, conditioned taste aversion; EM, emergency test; EPM, elevated plus-maze; EZM, elevated zero maze; FC, fear conditioning;
FST, forced swimming test; HP, hotplate; LD, light-dark box; NOR, novel object recognition; NSF, novelty suppressed feeding; OF, open field; RR, rotarod; SA, social
avoidance; WM, water maze.
INCREASED BDNF-TrKB SIGNALING
Direct infusion of BDNF into the DG of rat HC leads to
antidepressant-like effects (Shirayama et al., 2002). This find-
ing indicates that increasing BDNF expression in the brain
could also produce an antidepressant-like behavior. One study
with mice overexpressing BDNF in excitatory neurons of the
forebrain (HC, cortex, and amygdala) found an antidepressant-
like behavioral phenotype with increased anxiety-like behavior
(Govindarajan et al., 2006). Furthermore, chronic stress did not
alter the anxiety-like behavior of these mice. Another group
found that the same BDNF overexpressing mice showed increased
anxiety-like behavior in some but not all tests (Papaleo et al.,
2011). In the same study these mice demonstrated normal motor
functions, contextual and cued fear memory, social behavior, and
no alterations in depression-like behaviors. However, BDNF over-
expressing mice have impairments in working memory and the
auditory system. The results of these two studies are in part con-
tradictory. However, the two studies used mice of different sex,
which may explain the discrepancies, because sex is known to
influence behavior of genetically modified mice (Monteggia et al.,
2007; Autry et al., 2009). Another line of BDNF overexpressing
mice showed improved performance in learning and memory
tasks (Nakajo et al., 2008).
Transgenic mice overexpressing the full-length TrkB receptor
(TrkB.TK+; used as a heterozygous) under the Thy1 promoter
have enhanced TrkB signaling (Koponen et al., 2004). These mice
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show reduced anxiety- and depression-like behavior as well as
improvements in contextual and associative learning and mem-
ory tasks without changes in locomotor activity or coordination
(Koponen et al., 2004, 2005). In the forced swim test these
mice behaved as if they had been treated with ADs, and AD
treatment failed to produce any further effects (Koponen et al.,
2005). These TrkB.TK+ mice were originally bred and main-
tained on a CD2 (BALB/c × DBA/2) background but were later
backcrossed to the C57BL/6J background for more than 10 gen-
erations. However, when tested in the C57Bl/6J background, the
phenotype was much milder (Kemppainen et al., 2012). Male
mice showed increased locomotor activity while female mice did
not differ from controls.
DISCUSSION
The roles of neurotrophins in depression and in the mecha-
nisms underlying antidepressant effects have been widely stud-
ied. BDNF deficient mice are the most used model for these
studies. These models have demonstrated a key role for BDNF-
TrkB signaling in the mechanisms underlying the actions of
ADs (MacQueen et al., 2001; Saarelainen et al., 2003; Chourbaji
et al., 2004; Ibarguen-Vargas et al., 2009; Lindholm et al., 2012).
Specifically, direct infusion of BDNF into the brain produces
antidepressant-like behavior and enhances the effects of ADs,
while blockade of BDNF signaling prevents the effects of ADs. It
is possible that at least some of the antidepressant-like effects of
BDNF are mediated through BDNF-induced long-term changes
in synaptic connectivity, which in turn promote recovery from
depression (Castren, 2005). The effects of acute BDNF are well-
established in many regions of the HC and cortex (Messaoudi
et al., 1998; Panja and Bramham, 2014), and chronic antidepres-
sant treatment and BDNF infusion induce upregulation of an
overlapping set of immediate early genes (Wibrand et al., 2006;
Alme et al., 2007).
By contrast, there is no consensus as to whether decreases
in BDNF activity cause depression-like behavior in mice since
the results vary between different studies. The main difference
between these studies is likely the temporal and spatial resolution
of BDNF deficiency. However, other factors, such as developmen-
tal compensatory mechanisms, genetic backgrounds (Jacobson
and Cryan, 2007), sex differences (Dalla et al., 2010), and inter-
laboratory practices (Wahlsten et al., 2003) may also contribute
to the variable results between studies.
Another possible reason for the failure to demonstrate an asso-
ciation between BDNF and mood disorders is that in most mouse
models BDNF or TrkB are manipulated in most or all brain areas.
However, there is evidence that manipulations of BDNF or TrkB
signaling in different brain areas result in differential effects (Eisch
et al., 2003; Berton et al., 2006). Therefore, widespread deletions
could result in opposing effects that cancel each other out. Future
studies with better temporal and spatial control of BDNF and
TrkB will help to clarify this issue. Finally, mice are obviously
not ideal for modeling depression and anxiety disorders. Local
injection of a lentivirus coding for BDNF siRNA suggests that
reduction of BDNF levels in rat HC produces depression-like
behavior (Taliaz et al., 2010). Therefore, it is possible that geneti-
cally altered rats might produce more consistent results than mice
when attempting to assess the role of BDNF in mood disorders.
However, the Val66Met polymorphism in humans has not pro-
vided any clear evidence that altered BDNF release plays a role in
depression and anxiety in humans. Thus, there may not be any
direct association between BDNF and mood disorders.
In summary, while the importance of BDNF and TrkB in
the antidepressant response is clear, further experiments in more
refined mouse and rat models and in humans are necessary to
clarify the role of BDNF signaling in depression and anxiety
disorders.
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